Performance of the new PREVENT score for indicating subclinical atherosclerosis in rheumatoid arthritis

J Alex B Gibbons1, Joan M Bathon1, Jon T Giles2

  • 1Division of Rheumatology, Columbia University Vagelos College of Physicians & Surgeons, New York, NY, USA.

PubMed

Insights

The updated PREVENT algorithm does not better predict subclinical atherosclerosis in rheumatoid arthritis (RA) patients than the older Pooled Cohort Equations (PCE). Neither tool adequately identifies cardiovascular disease risk in this high-risk RA population.

Area of Science:

  • Cardiology
  • Rheumatology
  • Medical Imaging

Background:

  • Rheumatoid arthritis (RA) patients face elevated risk of atherosclerotic cardiovascular disease (ASCVD).
  • Traditional 10-year cardiovascular disease (CVD) risk calculators, like the 2013 Pooled Cohort Equations (PCE), often underperform in RA populations.
  • Subclinical atherosclerosis detection is crucial for accurate CVD risk assessment in RA.

Purpose of the Study:

  • To compare the performance of the PCE against the updated PREVENT algorithm in identifying subclinical coronary and carotid atherosclerosis in RA patients.
  • To evaluate the utility of different PREVENT scores (Total CVD, ASCVD, Total CVD + uACR) in this context.

Main Methods:

  • Patients with RA and no known CVD underwent chest CT for coronary artery calcium (CAC) scoring and carotid artery ultrasound for plaque detection.
  • PCE and three 10-year PREVENT scores were calculated for each patient.
  • The predictive performance of PCE and PREVENT scores for CAC and carotid plaque was compared using area under the receiver operating characteristic curves (AUROC).

Main Results:

  • Both PCE and PREVENT scores were significantly associated with the presence of CAC and carotid plaque.
  • The PCE demonstrated a higher AUROC (0.775) than the PREVENT ASCVD score (0.723) in predicting CAC >0 (P=0.034).
  • No significant difference in AUROC was observed between PCE and PREVENT scores for predicting carotid plaque.

Conclusions:

  • The updated PREVENT algorithm does not offer improved prediction of subclinical coronary or carotid atherosclerosis in RA patients compared to the PCE.
  • Given the known underperformance of PCE in RA, the PREVENT algorithm is unlikely to adequately predict future CVD events in this population.
  • Further research is needed to develop accurate CVD risk prediction tools for RA patients.
Abstract

Related Concept Videos

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
501
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
475
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
401
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
448
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
290
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
322